← Back to Search

Vitamin E Analog

APC-100 for Prostate Cancer

Phase 1 & 2
Waitlist Available
Led By Elisabeth I Heath, MD
Research Sponsored by Adamis Pharmaceuticals Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up pre-study, cycle 1: day 1 (unless prestudy was performed within 7 days of study entry), cycle 2: day 1, end of treatment
Awards & highlights

Study Summary

This study is a phase 1/2a, open label, dose escalation and safety study of APC-100 (2,2,5,7,8-Pentamethyl-6-chromanol) in men with advanced prostate cancer.

Eligible Conditions
  • Prostate Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~pre-study, cycle 1: day 1 (unless prestudy was performed within 7 days of study entry), cycle 2: day 1, end of treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and pre-study, cycle 1: day 1 (unless prestudy was performed within 7 days of study entry), cycle 2: day 1, end of treatment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Maximum Tolerated Dose (MTD) and recommended Phase 2a Dose
Secondary outcome measures
Assess number, types, and severity of toxicity and adverse events
Assess preliminary evidence of anti-tumor activity through PSA response
Plasma Pharmacokinetics (PK) profile of APC-100

Trial Design

1Treatment groups
Experimental Treatment
Group I: APC-100Experimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Adamis Pharmaceuticals CorporationLead Sponsor
3 Previous Clinical Trials
248 Total Patients Enrolled
Elisabeth I Heath, MDPrincipal InvestigatorWayne State University
Jeremy Cetnar, MDPrincipal InvestigatorUniversity of Wisconsin, Madison

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Dose-Escalation and Safety Study of APC-100 for the Treatment of Prostate Cancer
2011. "Dose-Escalation and Safety Study of APC-100 for the Treatment of Prostate Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01436214.
All > Prostate
~4 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top